Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

Sridhar Boppana, John E. Mindur, Konstantin Balashov, Suhayl Dhib-Jalbut, Kouichi Ito

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.

Original languageEnglish (US)
Pages (from-to)68-74
Number of pages7
JournalJournal of Neuroimmunology
Volume265
Issue number1-2
DOIs
StatePublished - Dec 15 2013

Fingerprint

Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Interferons
Gene Expression
HLA-G Antigens
Blood Cells
Interferon Type I
Virus Diseases
Therapeutics
Genes
Interferon-gamma
Immune System
Tissue Donors

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology
  • Immunology and Allergy
  • Immunology

Cite this

@article{eea808265baf48ffaca63b583caff5eb,
title = "Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis",
abstract = "Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.",
author = "Sridhar Boppana and Mindur, {John E.} and Konstantin Balashov and Suhayl Dhib-Jalbut and Kouichi Ito",
year = "2013",
month = "12",
day = "15",
doi = "https://doi.org/10.1016/j.jneuroim.2013.10.007",
language = "English (US)",
volume = "265",
pages = "68--74",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis. / Boppana, Sridhar; Mindur, John E.; Balashov, Konstantin; Dhib-Jalbut, Suhayl; Ito, Kouichi.

In: Journal of Neuroimmunology, Vol. 265, No. 1-2, 15.12.2013, p. 68-74.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

AU - Boppana, Sridhar

AU - Mindur, John E.

AU - Balashov, Konstantin

AU - Dhib-Jalbut, Suhayl

AU - Ito, Kouichi

PY - 2013/12/15

Y1 - 2013/12/15

N2 - Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.

AB - Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.

UR - http://www.scopus.com/inward/record.url?scp=84888391352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888391352&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jneuroim.2013.10.007

DO - https://doi.org/10.1016/j.jneuroim.2013.10.007

M3 - Article

VL - 265

SP - 68

EP - 74

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -